NO20074117L - Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander - Google Patents
Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstanderInfo
- Publication number
- NO20074117L NO20074117L NO20074117A NO20074117A NO20074117L NO 20074117 L NO20074117 L NO 20074117L NO 20074117 A NO20074117 A NO 20074117A NO 20074117 A NO20074117 A NO 20074117A NO 20074117 L NO20074117 L NO 20074117L
- Authority
- NO
- Norway
- Prior art keywords
- conditions
- compositions
- methods
- metabolic diseases
- treating diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical class C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Farmasøytiske sammensetninger omfattende 2S,4R ketokonazolenantiomeren eller dens farmasøytisk akseptable salter, hydrater og solvater, som er hovedsakelig fri for 2R,3S ketokonazolenantiomeren er nyttig for å redusere kortisolsyntese og for behandlingen av type II diabetes, hyperglykemi, fedme, insulinresistens3 dyslipidemi, hyperlipidemi, hyperfunksjon, metabolsk syndrom og andre sykdommer og tilstander, inkluderende, rnen ikke begrenset til, Cushing's syndrom, depresjon og glaukom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64305505P | 2005-01-10 | 2005-01-10 | |
PCT/IB2006/000026 WO2006072881A1 (en) | 2005-01-10 | 2006-01-10 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20074117L true NO20074117L (no) | 2007-10-01 |
NO339007B1 NO339007B1 (no) | 2016-11-07 |
Family
ID=36143322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074117A NO339007B1 (no) | 2005-01-10 | 2007-08-09 | 2S,4R Ketokonazol for behandling av diabetes, metabolsk syndrom og andre tilstander |
Country Status (21)
Country | Link |
---|---|
US (6) | US20090233843A1 (no) |
EP (1) | EP1853266B1 (no) |
JP (1) | JP5358095B2 (no) |
KR (2) | KR20140030327A (no) |
CN (1) | CN101141964B (no) |
AT (1) | ATE528005T1 (no) |
AU (1) | AU2006204334B2 (no) |
CA (1) | CA2594433C (no) |
CY (1) | CY1112519T1 (no) |
DK (1) | DK1853266T3 (no) |
ES (1) | ES2377526T3 (no) |
HK (1) | HK1118449A1 (no) |
IL (1) | IL184459A (no) |
MX (1) | MX2007008331A (no) |
NO (1) | NO339007B1 (no) |
NZ (1) | NZ560481A (no) |
PL (1) | PL1853266T3 (no) |
PT (1) | PT1853266E (no) |
SI (1) | SI1853266T1 (no) |
WO (1) | WO2006072881A1 (no) |
ZA (1) | ZA200706020B (no) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
KR20140030327A (ko) * | 2005-01-10 | 2014-03-11 | 콜텐도 인베스트 아베 | 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법 및 조성물 |
WO2007081980A2 (en) * | 2006-01-10 | 2007-07-19 | Diobex, Inc. | Methods and compositions for treating prostate cancer |
AU2007303219A1 (en) * | 2006-10-02 | 2008-04-10 | Cortendo Ab (Publ) | Ketoconazole enantiomer in humans |
PT2424356T (pt) | 2009-04-29 | 2017-11-23 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
NZ620473A (en) | 2009-06-15 | 2015-09-25 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides without raising ldl-c levels |
NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US20130059778A1 (en) * | 2010-03-15 | 2013-03-07 | Vann Bennett | Identification of a Genetic Risk Factor for Diabetes |
US20140127289A1 (en) | 2010-11-29 | 2014-05-08 | Armarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US10272133B2 (en) | 2011-10-06 | 2019-04-30 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
WO2013052813A1 (en) | 2011-10-06 | 2013-04-11 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
UA118015C2 (uk) | 2012-06-29 | 2018-11-12 | Амарін Фармасьютікалз Айрленд Лімітед | Способи зменшення ризику розвитку серцево-судинної події у суб'єкта, що одержує терапію статином |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
EP2953625A1 (en) * | 2013-02-06 | 2015-12-16 | Cortendo AB (publ) | Novel functionalized 4-(phenoxymethyl(-1,3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
CA2905857A1 (en) * | 2013-03-12 | 2014-10-09 | HMI Medical Innovations, LLC | Plant extracts with anti-diabetic and other useful activities |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US11571455B2 (en) | 2013-04-11 | 2023-02-07 | Vanderbilt University | Methods and compositions for treating alcoholic liver disease |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
CN103432135A (zh) * | 2013-09-06 | 2013-12-11 | 天津市康婷生物工程有限公司 | 一种内源性洋地黄样因子抑制剂 |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
US20170151202A1 (en) * | 2015-09-09 | 2017-06-01 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
CN105441391A (zh) * | 2015-12-10 | 2016-03-30 | 湖南中医药大学 | 一种糖尿病并发抑郁症的细胞模型及建立方法和应用 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
KR102114705B1 (ko) | 2017-11-06 | 2020-05-25 | 연세대학교 산학협력단 | 스타틴에 의한 약물유해반응의 예방 또는 치료용 약학 조성물 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US20210308156A1 (en) * | 2018-09-28 | 2021-10-07 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition, comprising thiamine derivative, for prevention or treatment of hypercortisolemia |
EP3863634A1 (en) * | 2018-10-12 | 2021-08-18 | Strongbridge Dublin Limited | Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism |
KR20210135278A (ko) * | 2019-03-04 | 2021-11-12 | 스트롱브릿지 더블린 리미티드 | 레보케토코나졸로 질환을 치료하는 방법 |
WO2020231909A1 (en) * | 2019-05-11 | 2020-11-19 | Steven Hoffman | Compositions and methods for treating bile acid associated diseases |
JP2023515434A (ja) * | 2020-02-19 | 2023-04-13 | ニュー フロンティア ラブズ,エルエルシー | 脂質代謝異常及び関連状態の治療又は予防におけるアゼライン酸エステル |
KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
US20230372312A1 (en) * | 2022-05-20 | 2023-11-23 | Corcept Therapeutics Incorporated | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient |
WO2024040256A2 (en) * | 2022-08-19 | 2024-02-22 | National Health Research Institutes | Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases |
WO2024105519A1 (en) * | 2022-11-14 | 2024-05-23 | Piramal Pharma Limited | A process for the preparation of levoketoconazole |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
US5432176A (en) * | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
AU5955094A (en) * | 1992-12-22 | 1994-07-19 | Sepracor, Inc. | Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections |
WO1994014446A1 (en) | 1992-12-22 | 1994-07-07 | Sepracor, Inc. | Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections |
US5869255A (en) * | 1994-02-01 | 1999-02-09 | The Regents Of The University Of California | Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis |
US6642236B1 (en) * | 1998-12-14 | 2003-11-04 | Cortendo Ab | Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis |
SI0779810T1 (en) * | 1994-08-09 | 2003-12-31 | Cortendo Ab | Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
US5584790A (en) | 1995-09-08 | 1996-12-17 | Beckman Instruments, Inc. | Variable inclination centrifugation assembly for rapid separation of blood |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US5994334A (en) * | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
SE9700642D0 (sv) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
JP2002541146A (ja) | 1999-04-02 | 2002-12-03 | ニューロゲン コーポレイション | アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用 |
ATE307798T1 (de) | 1999-05-17 | 2005-11-15 | Novo Nordisk As | Glucagon antagonisten/inverse agonisten |
GB9915625D0 (en) * | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
HUP0202175A3 (en) | 1999-09-28 | 2005-01-28 | Bayer Corp Berkeley | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
US20020055512A1 (en) * | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
GB0118300D0 (en) | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
JP2005519927A (ja) * | 2002-02-07 | 2005-07-07 | ファイザー・インク | 多嚢胞性卵巣症候群の処置における、シルデナフィル如きpde5インヒビターの使用 |
CA2518409A1 (en) * | 2003-03-12 | 2004-09-23 | John P. Mullally | Composition and method for treating inflammations by reducing c-reactive protein |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
KR20140030327A (ko) * | 2005-01-10 | 2014-03-11 | 콜텐도 인베스트 아베 | 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법 및 조성물 |
WO2007081980A2 (en) * | 2006-01-10 | 2007-07-19 | Diobex, Inc. | Methods and compositions for treating prostate cancer |
AU2007303219A1 (en) * | 2006-10-02 | 2008-04-10 | Cortendo Ab (Publ) | Ketoconazole enantiomer in humans |
-
2006
- 2006-01-10 KR KR1020147002595A patent/KR20140030327A/ko not_active Application Discontinuation
- 2006-01-10 NZ NZ560481A patent/NZ560481A/en not_active IP Right Cessation
- 2006-01-10 CN CN2006800048108A patent/CN101141964B/zh active Active
- 2006-01-10 MX MX2007008331A patent/MX2007008331A/es active IP Right Grant
- 2006-01-10 PL PL06701304T patent/PL1853266T3/pl unknown
- 2006-01-10 SI SI200631232T patent/SI1853266T1/sl unknown
- 2006-01-10 CA CA2594433A patent/CA2594433C/en active Active
- 2006-01-10 JP JP2007549979A patent/JP5358095B2/ja active Active
- 2006-01-10 US US11/813,662 patent/US20090233843A1/en not_active Abandoned
- 2006-01-10 ZA ZA200706020A patent/ZA200706020B/xx unknown
- 2006-01-10 AU AU2006204334A patent/AU2006204334B2/en active Active
- 2006-01-10 ES ES06701304T patent/ES2377526T3/es active Active
- 2006-01-10 PT PT06701304T patent/PT1853266E/pt unknown
- 2006-01-10 DK DK06701304.5T patent/DK1853266T3/da active
- 2006-01-10 EP EP06701304A patent/EP1853266B1/en active Active
- 2006-01-10 KR KR1020077017684A patent/KR101387910B1/ko active IP Right Grant
- 2006-01-10 WO PCT/IB2006/000026 patent/WO2006072881A1/en active Application Filing
- 2006-01-10 AT AT06701304T patent/ATE528005T1/de active
-
2007
- 2007-07-05 IL IL184459A patent/IL184459A/en active IP Right Grant
- 2007-08-09 NO NO20074117A patent/NO339007B1/no not_active IP Right Cessation
-
2008
- 2008-08-29 HK HK08109611.2A patent/HK1118449A1/xx active IP Right Revival
-
2012
- 2012-01-12 CY CY20121100037T patent/CY1112519T1/el unknown
-
2016
- 2016-04-01 US US15/088,539 patent/US9918984B2/en active Active
-
2018
- 2018-02-01 US US15/886,437 patent/US10098877B2/en active Active
- 2018-10-04 US US16/152,202 patent/US10517868B2/en active Active
-
2019
- 2019-12-16 US US16/715,690 patent/US10835530B2/en active Active
-
2020
- 2020-11-10 US US17/094,544 patent/US11478471B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074117L (no) | Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander | |
RU2462456C2 (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
NO20084364L (no) | Azetidin derivater som G-protein koblet reseptor (GPR119) agonister | |
NO20084403L (no) | Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I | |
NO20084874L (no) | Piendinylsubstituerte pyrrolidinoner som hemmere av 11-beta-hydroksysteroiddehydrogenase 1 | |
NO20083863L (no) | Pyrazoler som 11-beta-hsd-1 | |
NO20090591L (no) | Metabolisme modulatorer samt behandling av lidelser relatert dertil | |
WO2007139941A3 (en) | Composition and methods for treatment of congestive heart failure | |
WO2007065808A3 (en) | Neuropeptide-2 receptor-agonists | |
IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
UA100008C2 (ru) | Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит | |
ES2318577T3 (es) | Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'. | |
NO20084318L (no) | Inhibitorer av II-beta-hydroksystereoid dehydrogenase I | |
DE602004011985D1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
NO20085056L (no) | Insulinderivat | |
MX2009009416A (es) | Derivados de bencimidazol y sus metodos de uso. | |
EP1948161A4 (en) | METHOD OF PREVENTION AND TREATMENT WITH MACELIGNAN OF MEDIA MEDIA BY PPAR | |
WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof | |
MX2010001352A (es) | Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares. | |
IN2012DN03023A (no) | ||
WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes | |
IS8373A (is) | Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn | |
WO2008039087A3 (en) | Indoline derivatives and uses thereof | |
NO20063261L (no) | Selektive peroksisome proliferatoraktiviterte reseptormodulatorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |